×
About 1,655 results

ALLMedicine™ Apolipoprotein A-I Center

Research & Reviews  626 results

AIBP regulates TRPV1 activation in CIPN by controlling lipid raft dynamics and proximit...
https://doi.org/10.1097/j.pain.0000000000002834
Pain Navia-Pelaez JM, Paes Lemes JB et. al.

Feb 1st, 2023 - Nociceptive afferent signaling evoked by inflammation and nerve injury is mediated by the opening of ligand- and voltage-gated receptors/channels localized to cholesterol-rich lipid raft membrane domains. Dorsal root ganglia (DRG) nociceptors expr...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

Jan 31st, 2023 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Jan 20th, 2023 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect ag...
https://doi.org/10.1073/pnas.2209528120
Proceedings of the National Academy of Sciences of the Un... Liao YE, Xu Y et. al.

Jan 18th, 2023 - Sepsis is a lethal syndrome manifested by an unregulated, overwhelming inflammation from the host in response to infection. Here, we exploit the use of a synthetic heparan sulfate octadecasaccharide (18-mer) to protect against sepsis. The 18-mer n...

Identification of potential visceral pain biomarkers in colon exudates from mice with e...
https://doi.org/10.1016/j.jpain.2023.01.001
The Journal of Pain; Cisneros E, Martínez-Padilla A et. al.

Jan 14th, 2023 - Chronic visceral pain (CVP) is extremely difficult to diagnose, and available analgesic treatment options are quite limited. Identifying the proteins secreted from the colonic nociceptors, or their neighbor cells within the tube walls, in the cont...

see more →

Clinicaltrials.gov  22 results

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

Jan 31st, 2023 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Jan 20th, 2023 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
https://clinicaltrials.gov/ct2/show/NCT00768274

Nov 4th, 2022 - One-third of the US population, almost 80 million adults, have cardiovascular disease and mortality associated with heart disease which still remains a leading cause of death around the world. The major risk factors for cardiovascular disease asso...

Families-At-risk for Interstitial Lung Disease Study
https://clinicaltrials.gov/ct2/show/NCT03641742

Jul 21st, 2022 - The NHLBI has prioritized research focused on the primary prevention of chronic lung diseases, including ILD. The overall goal of this study is to conduct studies preparatory to and requisite for the testing of ILD preventative interventions. In t...

Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity
https://clinicaltrials.gov/ct2/show/NCT05210023

Jan 27th, 2022 - After the selection of the population, the patients undergo a molecular diagnosis: DNA will be extracted from peripheral blood with the High Pure PCR (Polymerase Chain Reaction) Template Preparation Kit (Roche). Then certain polymorphisms will be ...

see more →

News  14 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

Xarelto for CAD/PAD? LVAD Cord Out the Head; HDL Drug Moves Forward
https://www.medpagetoday.com/cardiology/prevention/69812

Dec 11th, 2017 - Based on the COMPASS trial results, the ultra-low 2.5-mg twice-daily dose of rivaroxaban (Xarelto) has been submitted for a supplemental indication in prevention of major cardiovascular events in coronary artery disease or peripheral artery diseas...

No Plaque Reduction With Mimetic HDL Agent in ACS: CARAT Phase 2 Trial
https://www.medscape.com/viewarticle/877757

Mar 27th, 2017 - WASHINGTON, DC — Infusing an engineered HDL-cholesterol mimetic into patients who recently have had acute coronary syndrome (ACS) did not reduce the volume of plaque in arteries as measured by intravascular ultrasound (IVUS) compared with placebo,...

Favorable Lipid Changes Seen with Baricitinib
https://www.medpagetoday.com/rheumatology/arthritis/62498

Jan 12th, 2017 - Action Points Baricitinib, an investigational reversible inhibitor of tyrosine kinases JAK 1 and JAK2 signaling, increases the level of serum lipids, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-...

VIDEO: MILANO-PILOT marks end of the road for HDL mimetic
https://www.mdedge.com/chestphysician/article/119301/lipid-disorders/video-milano-pilot-marks-end-road-hdl-mimetic
Susan London, MDedge News

Dec 2nd, 2016 - NEW ORLEANS – The future doesn’t look bright at the moment for use of agents that mimic HDL cholesterol to reverse coronary disease, based on disappointing results of the randomized, phase II MILANO-PILOT trial. Among 120 patients with recent acut.

see more →